What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026
If you've ever wondered why your doctor reached for a GLP-1 medication, or whether you "qualify" for one, a large part of the answer traces back to a single reference document: the American Diabetes Association's Standards of Care in Diabetes. It's updated every year, and it's the playbook most US clinicians follow when deciding how to treat diabetes and obesity together.
This guide translates what that document actually says about GLP-1 medications into plain language — what it recommends, for whom, and the one change in the 2026 edition that's genuinely new.
What the "Standards of Care" is (and isn't)
The Standards of Care is a set of evidence-based recommendations, not a law and not a guarantee of coverage. Each recommendation carries a grade (A, B, C, or E) reflecting how strong the underlying evidence is. Clinicians use it as a starting point, then tailor decisions to the person in front of them.
Two things follow from that:
- It changes. What's recommended this year can be refined or reversed next year as new trials publish. Always confirm the current version with your care team rather than relying on an older summary.
- It guides treatment, not insurance. A medication being "preferred" in the guideline doesn't mean your plan covers it. Coverage runs on a separate track — see Understanding insurance coverage for GLP-1 medications.
For type 2 diabetes with obesity: GLP-1s are the preferred choice
The clearest message in the guideline is about type 2 diabetes with overweight or obesity. Here, weight management is treated as a primary goal alongside blood-sugar control — not an afterthought.
When a medication is added specifically to help with weight, the guideline names the preferred option directly: a GLP-1 receptor agonist (such as ) (such as ), chosen for their combination of strong weight reduction and glucose-lowering. (ADA, , §8, .)